Erratum (DOI:10.1016/S1474-4422(09)70211-X);Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study

The Lancet Neurology

Volumn 8, Issue 10, 2009, Pages 918-928

  Kinali, Maria ^a,b   Arechavala Gomeza, Virginia ^a   Feng, Lucy ^a   Cirak, Sebahattin ^a   Hunt, David ^c   Adkin, Carl ^a   Guglieri, Michela ^d   Ashton, Emma ^e   Abbs, Stephen ^e   Nihoyannopoulos, Petros ^f   Garralda, Maria Elena ^f   Rutherford, Mary ^f   Mcculley, Caroline ^f   Popplewell, Linda ^f,g   Graham, Ian R ^f,g   Dickson, George ^f,g   Wood, Matthew JA ^h   Wells, Dominic J ^f   Wilton, Steve D ⁱ   Kole, Ryszard ^j   Straub, Volker ^d   Bushby, Kate ^d   Sewry, Caroline ^a,k   Morgan, Jennifer E ^a   Muntoni, Francesco ^a,b   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c ST MARY S HOSPITAL   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e GUY S HOSPITAL   (United Kingdom)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF LONDON   (United Kingdom)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^j AVI BIOPHARMA INC   (United States)

^k ROBERT JONES AND AGNES HUNT ORTHOPAEDIC HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AVI 4658; DYSTROPHIN; MORPHOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG SAFETY; DUCHENNE MUSCULAR DYSTROPHY; EXTENSOR MUSCLE; FIBROBLAST; GENE DELETION; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

EID: 69949107887     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(09)70309-6     Document Type: Erratum

References (42)

1. Simonds A.K., Muntoni F., Heather S., and Fielding S. Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy. Thorax 53 (1998) 949-952
2. Eagle M., Baudouin S.V., Chandler C., Giddings D.R., Bullock R., and Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 12 (2002) 926-929
3. Hoffman E.P., Brown Jr. R.H., and Kunkel L.M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51 (1987) 919-928
4. Morris G.E., Ellis J.M., and Nguyen T.M. A quantitative ELISA for dystrophin. J Immunol Methods 161 (1993) 23-28
5. Koenig M., Beggs A.H., Moyer M., et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 45 (1989) 498-506
6. Bushby K.M., Gardner-Medwin D., Nicholson L.V., et al. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. II Correlation of phenotype with genetic and protein abnormalities. J Neurol 240 (1993) 105-112
7. Klein C.J., Coovert D.D., Bulman D.E., Ray P.N., Mendell J.R., and Burghes A.H. Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. Am J Hum Genet 50 (1992) 950-959
8. Lu Q.L., Morris G.E., Wilton S.D., et al. Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion. J Cell Biol 148 (2000) 985-996
9. Melis M.A., Cau M., Muntoni F., et al. Elevation of serum creatine kinase as the only manifestation of an intragenic deletion of the dystrophin gene in three unrelated families. Eur J Paediatr Neurol 2 (1998) 255-261
10. Lesca G., Testard H., Streichenberger N., et al. Family study allows more optimistic prognosis and genetic counselling in a child with a deletion of exons 50-51 of the dystrophin gene. Arch Pediatr 14 (2007) 262-265
11. Muntoni F., Torelli S., and Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2 (2003) 731-740
12. Aartsma-Rus A., Fokkema I., Verschuuren J., et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 30 (2009) 293-299
13. Sazani P., Graziewicz M.A., and Kole R. Splice switching oligonucleotides as potential therapeutics. In: Crooke S.T. (Ed). Antisense drug technology: principles, strategies, and applications (2008), Taylor and Francis, London 89-114
14. Aartsma-Rus A., Janson A.A., Kaman W.E., et al. Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet 12 (2003) 907-914
15. Aartsma-Rus A., and van Ommen G.J. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 13 (2007) 1609-1624
16. McClorey G., Moulton H.M., Iversen P.L., Fletcher S., and Wilton S.D. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther 13 (2006) 1373-1381
17. Lu Q.L., Mann C.J., Lou F., et al. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 9 (2003) 1009-1014
18. Yokota T., Lu Q.L., Partridge T., et al. Efficacy of systemic morpholino exon-skipping in duchenne dystrophy dogs. Ann Neurol 65 (2009) 667-676
19. Takeshima Y., Yagi M., Wada H., et al. Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Pediatr Res 59 (2006) 690-694
20. van Deutekom J.C., Janson A.A., Ginjaar I.B., et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357 (2007) 2677-2686
21. Sazani P., Gemignani F., Kang S.H., et al. Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat Biotechnol 20 (2002) 1228-1233
22. Fletcher S., Honeyman K., Fall A.M., Harding P.L., Johnsen R.D., and Wilton S.D. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J Gene Med 8 (2006) 207-216
23. Alter J., Lou F., Rabinowitz A., et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12 (2006) 175-177
24. Heemskerk H.A., de Winter C.L., de Kimpe S.J., et al. In vivo comparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 11 (2009) 257-266
25. Muntoni F., Bushby K.D., and van Ommen G. 149th ENMC International Workshop and 1st TREAT-NMD Workshop on: planning phase I/III clinical trials using systemically delivered antisense oligonucleotides in Duchenne muscular dystrophy. Neuromuscul Disord 18 (2008) 268-275
26. Emery A.E., and Muntoni F. Duchenne muscular dystrophy. 3rd edn (2003), Oxford University Press, Oxford
27. Mercuri E., Cini C., Counsell S., et al. Muscle MRI findings in a three-generation family affected by Bethlem myopathy. Eur J Paediatr Neurol 6 (2002) 309-314
28. Hawley Jr. R.J., Schellinger D., and O'Doherty D.S. Computed tomographic patterns of muscles in neuromuscular diseases. Arch Neurol 41 (1984) 383-387
29. Dubowitz V., and Sewry C. Muscle biopsy: a practical approach. 3rd edn (2007), Saunders Elsevier, Netherlands
30. Macalister A. Additional observation on muscular anomalies in human anatomy (third series), with a catalogue of the principal muscular variations hitherto published. Trans Roy Irish Acad Sci 25 (1875) 1-134
31. Mercuri E., Pichiecchio A., Allsop J., Messina S., Pane M., and Muntoni F. Muscle MRI in inherited neuromuscular disorders: past, present, and future. J Magn Reson Imaging 25 (2007) 433-440
32. Mercuri E., Pichiecchio A., Counsell S., et al. A short protocol for muscle MRI in children with muscular dystrophies. Eur J Paediatr Neurol 6 (2002) 305-307
33. Bailey D., and Garralda M.E. The use of social stress and support interview in families with deviant children: methodological issues. Social Psychiatry 22 (1987) 209-215
34. Goodman R., Ford T., Simmons H., Gatward R., and Meltzer H. Using the Strengths and Difficulties questionnaire to screen for child psychiatric disorders. Br J Psychiatry 177 (2000) 534-539
35. Goldberg D. Manual of the General Health Questionnaire (1978), NFER Publishing Company, Wiltshire: UK
36. Miller I.W., Epstein N.B., Bishop D.S., and Keitner G.I. The McMaster Family Assessment Device: Reliability and Validity. J Marital Fam Ther 11 (1985) 345-356
37. White D., Leach C., Atkinson M., and Cottrell D. Validation of the Hospital Anxiety and Depression Scale for use with adolescents. Br J Psychiatry 175 (1999) 452-454
38. Roest P.A., van der Tuijn A.C., Ginjaar H.B., et al. Application of in vitro Myo-differentiation of non-muscle cells to enhance gene expression and facilitate analysis of muscle proteins. Neuromuscul Disord 6 (1996) 195-202
39. Arechavala-Gomeza V., Graham I.R., Popplewell L.J., et al. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther 18 (2007) 798-810
40. Ferrer A., Foster H., Wells K.E., Dickson G., and Wells D.J. Long-term expression of full-length human dystrophin in transgenic mdx mice expressing internally deleted human dystrophins. Gene Ther 11 (2004) 884-893
41. Nguyen T.M., and Morris G.E. Use of epitope libraries to identify exon-specific monoclonal antibodies for characterization of altered dystrophins in muscular dystrophy. Am J Hum Genet 52 (1993) 1057-1066
42. Neri M., Torelli S., Brown S., et al. Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscul Disord 17 (2007) 913-918